Research programme: anticancer monoclonal antibodies - AIMM Therapeutics

Drug Profile

Research programme: anticancer monoclonal antibodies - AIMM Therapeutics

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator AIMM Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Acute myeloid leukaemia
  • No development reported Malignant melanoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Malignant-melanoma in Netherlands (Parenteral)
  • 06 May 2014 Acute myeloid leukaemia monoclonal antibody - AIMM Therapeutics is available for licensing as of 31 Dec 2013.
  • 31 Dec 2013 Early research in Acute myeloid leukaemia in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top